GMAB

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Genmab AS

NASDAQ | GMAB

32.36

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 28, 2025)

$19.79B

Market Cap

14

P/E Ratio

2.28

EPS

$33.65

52 Week High

$17.23

52 Week Low

HEALTHCARE

Sector

GMAB Chart

Recent Chart
Price Action

GMAB Technicals

Tags:

GMAB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (DKK)
Gross Profit $21B
Total Revenue $22B
Cost Of Revenue $985M
Costof Goods And Services Sold $985M
Operating Income $6.7B
Selling General And Administrative $3.8B
Research And Development $9.7B
Operating Expenses $14B
Investment Income Net -
Net Interest Income $875M
Interest Income $995M
Interest Expense $120M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $413M
Income Before Tax $9.2B
Income Tax Expense $1.3B
Interest And Debt Expense -
Net Income From Continuing Operations $7.8B
Comprehensive Income Net Of Tax -
Ebit $9.3B
Ebitda $9.7B
Net Income $7.8B

Revenue & Profitability

Earnings Performance

GMAB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (DKK)
Total Assets $46B
Total Current Assets $28B
Cash And Cash Equivalents At Carrying Value $9.9B
Cash And Short Term Investments $9.9B
Inventory $62M
Current Net Receivables $6.7B
Total Non Current Assets $18B
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $12B
Intangible Assets Excluding Goodwill $12B
Goodwill $2.5B
Investments -
Long Term Investments $228M
Short Term Investments $11B
Other Current Assets $101M
Other Non Current Assets -
Total Liabilities $9.1B
Total Current Liabilities $5.3B
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt $92M
Total Non Current Liabilities $3.8B
Capital Lease Obligations $1B
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1B
Other Current Liabilities $3.5B
Other Non Current Liabilities -
Total Shareholder Equity $37B
Treasury Stock -
Retained Earnings $24B
Common Stock $66M
Common Stock Shares Outstanding $646M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (DKK)
Operating Cashflow $7.8B
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $413M
Capital Expenditures $187M
Change In Receivables -
Change In Inventory -$5M
Profit Loss -
Cashflow From Investment -$9.9B
Cashflow From Financing -$3.9B
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$4B
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $7.8B

yearly Income Statement (As of Dec 31, 2024)

Field Value (DKK)
Gross Profit $21B
Total Revenue $22B
Cost Of Revenue $985M
Costof Goods And Services Sold $985M
Operating Income $6.7B
Selling General And Administrative $3.8B
Research And Development $9.7B
Operating Expenses $14B
Investment Income Net -
Net Interest Income $875M
Interest Income $995M
Interest Expense $120M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $413M
Income Before Tax $9.2B
Income Tax Expense $1.3B
Interest And Debt Expense -
Net Income From Continuing Operations $7.8B
Comprehensive Income Net Of Tax -
Ebit $9.3B
Ebitda $9.7B
Net Income $7.8B

GMAB News

GMAB Profile

Genmab AS Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Genmab AS is a leading biotechnology firm headquartered in Copenhagen, Denmark, specializing in the creation of differentiated antibody therapeutics for oncology and other severe diseases. Renowned for its innovative approach and cutting-edge proprietary technologies, the company has established a robust pipeline of next-generation therapies through strategic alliances and collaborations. With a steadfast focus on enhancing patient outcomes via targeted immunotherapies, Genmab is strategically positioned to leverage growth opportunities within the evolving oncology landscape, making it an attractive prospect for institutional investors.

LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
VINE
+10.76%
$0.39
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
YGMZ
-9.59%
$0.11
BYND
-3.74%
$0.98
AXDX
-61.36%
$0.03
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
INHD
-0.97%
$0.22
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
CHR
-3.48%
$0.04
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
F
+0.45%
$13.25
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
MTSR
-0.35%
$70.50
IREN
+2.06%
$48.45
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.40%
$7.82
AFMD
-34.94%
$0.18
PFE
0.00%
$25.71
SMX
+250.80%
$61.04
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
VEEE
+45.50%
$2.59
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
CAN
+9.78%
$1.01
WBD
+0.50%
$24.00
AIIO
-9.09%
$0.70
AG
+12.65%
$15.22
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.76%
$8.37
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
RIVN
+4.20%
$16.86
KSS
+7.49%
$24.10
RR
-3.35%
$3.46
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.76%
$17.28
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
KDLY
+7.20%
$0.49
T
+0.69%
$26.00
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
BTE
+2.05%
$3.22
LPTX
+368.57%
$2.05
VHAI
0.00%
$0.00
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
VINE
+10.76%
$0.39
HBI
-1.82%
$6.47
AMZE
+19.82%
$0.47
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
YGMZ
-9.59%
$0.11
BYND
-3.74%
$0.98
AXDX
-61.36%
$0.03
BMNR
+4.53%
$33.18
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
RUBI
-26.17%
$0.15
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
AMD
+3.93%
$214.24
SOND
-23.45%
$0.12
SNAP
+0.72%
$7.66
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
INHD
-0.97%
$0.22
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
CHR
-3.48%
$0.04
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.77%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.82%
$5.50
F
+0.45%
$13.25
TWOH
0.00%
$0.00
WLGS
-5.57%
$0.04
BURU
+10.43%
$0.24
GPUS
-8.58%
$0.30
MTSR
-0.35%
$70.50
IREN
+2.06%
$48.45
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.80%
$4.64
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.40%
$7.82
AFMD
-34.94%
$0.18
PFE
0.00%
$25.71
SMX
+250.80%
$61.04
CRCL
+10.02%
$79.92
KWM
+13.63%
$0.75
DNN
-0.19%
$2.55
IBRX
+10.79%
$2.36
RIOT
+7.82%
$16.13
VEEE
+45.50%
$2.59
AMZN
+1.77%
$233.22
AAPL
+0.46%
$278.85
CAN
+9.78%
$1.01
WBD
+0.50%
$24.00
AIIO
-9.09%
$0.70
AG
+12.65%
$15.22
APLD
+8.66%
$27.10
GOOG
-0.05%
$320.12
NGD
+6.76%
$8.37
RIG
+2.09%
$4.39
GRYP
-10.38%
$1.38
BAC
+1.28%
$53.67
MODV
-25.22%
$0.43
RIVN
+4.20%
$16.86
KSS
+7.49%
$24.10
RR
-3.35%
$3.46
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.76%
$17.28
ITUB
+1.82%
$7.80
AGNC
-0.66%
$10.49
CRCA
+19.56%
$4.40
KDLY
+7.20%
$0.49
T
+0.69%
$26.00
AMC
+6.30%
$2.44
NVO
+1.21%
$49.30
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.67%
$3.70
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
BTE
+2.05%
$3.22
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.